Actively Recruiting
Randomized Study of MTX-001 Injections for Non-Healing Venous Stasis Ulcers with Standard Wound Care
Led by Merakris Therapeutics · Updated on 2026-08-26
80
Participants Needed
12
Research Sites
8 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of MTX-001 in treating non-healing venous stasis ulcers VSU that have not improved after at least 4 weeks of standard wound care. This randomized, double-blind, placebo-controlled study includes patients with specific ulcer characteristics and aims to better understand MTX-001s potential benefits in wound healing compared to placebo. The study has two parts an initial lead-in phase where patients received MTX-001 weekly or every two weeks alongside standard care, followed by a randomized phase where about 70 patients receive either MTX-001 or a placebo injection weekly along with standard wound care. Treatments involve subcutaneous injections into or around the ulcer during weekly clinic visits over 12 weeks. Participants undergo safety and efficacy assessments at screening, baseline, and weeks 4, 8, and 12, including measuring wound surface area, pain levels, and overall wound healing progress. Researchers track changes in ulcer size, pain, quality of life, and total wound closure. The study also monitors tolerability and safety throughout the 12-week treatment period.
CONDITIONS
Brief Title
MTX-001 for the Treatment of Non-Healing Venous Stasis Ulcers
Research Team
T
T Che Jarrell, MBA
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here